Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 17;10:831. doi: 10.3389/fimmu.2019.00831

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Wang, Yigit, van der Poel, Cuenca, Carroll, Herzog, Engel and Terhorst.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Anti-SLAMF3 accelerates GC B cell differentiation initiated by cGVHD. Anti-SLAMF3 or isotype injected bm12 CD4⁺ T cell transferred WT recipient mice were analyzed on day 14 when GC reactions peaked. (A) Percentages of B220⁺CD69⁺ B cells are as shown. (B) Expression of CD86 on B cells. (C) FAS expression in non-GC B and GC B cells from isotype and aSLAMF3 injected recipients. (D,E) Representative Flow cytometry plot for GC staining: CD19+GL-7+FAS+ B cells (left panel), percentages of GC B (Right panel) and numbers of GC B cells in spleen of mice. (F) Representative FACS plots of B220⁺IFN-γR⁺ GC B cells from isotype and αSLAMF3-injected recipients. (G) The percentage of B220⁺IFN-γR⁺ GC B cells in the spleens of isotype and αSLAMF3-injected recipients. Data represent at least four independent experiments.